CINGW
Price:
$0.0498
Market Cap:
$11.72M
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.[Read more]
Industry
Biotechnology
IPO Date
Stock Exchange
NASDAQ
Ticker
CINGW
According to Cingulate Inc.’s latest financial reports and current stock price. The company's current ROE is 11.47%. This represents a change of 650.85% compared to the average of 1.53% of the last 4 quarters.
The mean historical ROE of Cingulate Inc. over the last ten years is -430.63%. The current 11.47% ROE has changed -2763.84% with respect to the historical average. Over the past ten years (40 quarters), CINGW's ROE was at its highest in in the September 2023 quarter at 6.21%. The ROE was at its lowest in in the March 2023 quarter at -194883.42%.
Average
-430.63%
Median
-99.51%
Minimum
-1858.37%
Maximum
342.60%
Discovering the peaks and valleys of Cingulate Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.23%
Maximum Annual ROE = 342.60%
Minimum Annual Increase = -125.85%
Minimum Annual ROE = -1858.37%
Year | ROE | Change |
---|---|---|
2023 | 342.60% | 1.23% |
2022 | 25.72% | -125.85% |
2021 | -99.51% | -82.34% |
2020 | -563.58% | -69.67% |
The current ROE of Cingulate Inc. (CINGW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
89.61%
5-year avg
-430.63%
10-year avg
-430.63%
Cingulate Inc.’s ROE is less than Cingulate Inc. (11.47%), greater than Celularity Inc. (-279.32%), less than NeuroSense Therapeutics Ltd. (313.10%), greater than EQRx, Inc. (-6.54%), greater than Dermata Therapeutics, Inc. (-197.44%),
Company | ROE | Market cap |
---|---|---|
11.47% | $11.72M | |
-279.32% | $47.85M | |
313.10% | $25.96M | |
-6.54% | $1.14B | |
-197.44% | $2.10M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cingulate Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cingulate Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Cingulate Inc.'s ROE?
How is the ROE calculated for Cingulate Inc. (CINGW)?
What is the highest ROE for Cingulate Inc. (CINGW)?
What is the 3-year average ROE for Cingulate Inc. (CINGW)?
What is the 5-year average ROE for Cingulate Inc. (CINGW)?
How does the current ROE for Cingulate Inc. (CINGW) compare to its historical average?